MRK is trading 3.2% up at $124.40 after winning a key European regulatory approval for its oncology portfolio.
- The European Commission cleared the combination of Merck’s blockbuster immunotherapy Keytruda and Padcev for cisplatin-ineligible muscle-invasive bladder cancer.
- The approval expands a high-value oncology franchise and is expected to bolster the company's long-term revenue expectations.